• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Genmab A/S

    < Previous 1 2 3 4 Next >
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Publishes 2025 Annual Report
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Financial Results for the First Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Portfolio Prioritization Update
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Portfolio Prioritization Update
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
    From Genmab A/S
    Via Business Wire
    Tickers GMAB MRUS
    News headline image
    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Financial Results for the Nine Months of 2025
    From Genmab A/S
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.